A&E attendances twice as high in deprived areas
Attendances for the 20% of the population living in the most deprived areas also account for 27% of all A&E attendances.
Read More
Tag: Brineura
BioMarin’s Brineura made available on NHS
The £500,000 per patient drug was deemed too costly for use in February 2018.
Read More
Brineura hit with NICE rejection
NICE is rejecting NHS funding for a £500,000-a-year drug to treat Batten disease on concerns over its long-term effectiveness.
Read More
NICE deems Batten disease therapy too costly for NHS use
The National Institute for Health and Care Excellence has issued draft guidelines concluding that Biomarin’s Brineura is not a cost-effective treatment option for patients with the ultra rare disorder Batten disease.
Read More
US clears first therapy for Batten disease
US regulators have approved BioMarin Pharmaceutical’s Brineura as the first treatment for a rare inherited form of Batten disease.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
